What are the side effects of a GLP-1 when you have PCOS?

Dr. Linda's take

If you have PCOS and one of these medications has come up in your search history or your group chat, you are probably weighing two things at once: whether it could help, and what it might actually feel like day to day. Side effects are a fair thing to ask about first, because tolerability is not a footnote. It shapes whether a medication is something a person can live with over time. Most of the weight-loss content online skips past this, or frames it around appearance, which is not the question that matters when you have a metabolic condition like PCOS. My goal here is not to tell you what to take. It is to walk you through what the drug labels and the PCOS research actually say about side effects, so that when you sit down with a clinician you can ask sharper questions and hear sharper answers.

What is a GLP-1 receptor agonist, and why is it studied in PCOS?

GLP-1 receptor agonists are a class of medicines that were originally developed to treat type 2 diabetes and later used to support weight management. Many people with PCOS also have metabolic features such as insulin resistance or obesity. Insulin resistance is closely tied to PCOS physiology, which is part of why researchers have studied whether a medication class built around insulin sensitivity and weight change could also ease PCOS symptoms. Semaglutide is one member of this class, and it is used off-label for PCOS because it is not FDA-approved specifically to treat PCOS. This article stays on side effects, so for how these medicines are actually being studied in PCOS, see our companion overview of semaglutide and PCOS.

What are the common gastrointestinal side effects?

The most common side effects of these medicines are gastrointestinal. On the FDA prescribing information for semaglutide, the most frequently reported adverse reactions include nausea, diarrhea, vomiting, constipation, and abdominal pain. In the label's adult trials, nausea was reported by about 44% of people taking semaglutide, with diarrhea, vomiting, and constipation each also common. In PCOS, where daily symptoms and metabolic strain are already part of life, how a treatment sits with your stomach is a real part of the decision and not a minor one.

What did the PCOS trials report about side effects?

In studies of this medication class specifically in women with PCOS, gastrointestinal disturbances such as nausea, vomiting, and diarrhea were the most commonly reported side effects. In that same body of research, gastrointestinal side effects were also the most common reason participants stopped taking the medication. For most people in these trials, the issue was tolerability rather than danger, and tolerability is something a clinician can often plan around.

What is the boxed warning, and who should not take these medicines?

Semaglutide's FDA prescribing information carries a boxed warning, the strongest warning the FDA uses. In rodent studies, semaglutide caused thyroid C-cell tumors, and whether it causes the same tumors in humans is not known. Because of that finding, semaglutide is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2. This is exactly the kind of history to raise with a clinician before starting, because it is not something a person can feel or self-screen for.

What do the labels say about the gallbladder and pancreas?

The semaglutide label notes that treatment is associated with an increased occurrence of gallbladder problems, including gallstones and gallbladder inflammation. The label also warns that acute pancreatitis has been observed in people treated with GLP-1 receptor agonists, including semaglutide. These are less common than the gastrointestinal effects above, and they are the kind of warning a clinician screens for.

Can these side effects be managed?

Often, yes. The semaglutide label describes a gradual dose escalation schedule that is designed to reduce gastrointestinal side effects, and it advises slowing that schedule down if a dose is not well tolerated. That is why starting low and increasing slowly is standard, and why the early weeks are usually where tolerability gets tested. None of this tells you whether this medication is right for you. It is context for a conversation with a clinician who knows your full history.

What should you ask your clinician?

If you want a structured way to start that conversation, Body Good Studio's quiz is built to map your symptoms to a starting point before you talk with a clinician.

Frequently asked questions

What are the most common side effects of a GLP-1 when you have PCOS?

The most common side effects are gastrointestinal, especially nausea, vomiting, and diarrhea. In PCOS trials of this medication class, those gastrointestinal effects were the most frequently reported and were also the most common reason participants stopped treatment.

Is a GLP-1 approved to treat PCOS?

Semaglutide is approved for chronic weight management, not for PCOS specifically, so using it for PCOS symptoms is considered off-label. That does not mean it is unsafe or unstudied, only that dedicated PCOS approval does not exist yet.

Why does semaglutide carry a boxed warning about the thyroid?

In rodent studies, semaglutide caused thyroid C-cell tumors, and it is not known whether it causes the same tumors in humans. Because of that, it is contraindicated for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Do the gastrointestinal side effects improve over time?

The labels do not promise a specific timeline, but they are built around reducing these effects. The semaglutide label uses a gradual dose escalation schedule specifically to reduce gastrointestinal side effects, and advises slowing that schedule when a dose is not well tolerated.

Are these side effects the same for everyone?

No. Side effects vary from person to person, and your full medical history is part of what a clinician weighs before starting any medication. This article is general education, not medical advice, and it cannot tell you what is right for your body.

References

1. National Institute of Child Health and Human Development (NICHD) (2026). About Polycystic Ovary Syndrome (PCOS). National Institutes of Health. https://www.nichd.nih.gov/health/topics/pcos (Accessed 2026-07-15).
2. Bednarz K, Kowalczyk K, Cwynar M, Czapla D, Czarkowski W, Kmita D, Nowak A, Madej P (2022). The Role of GLP-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome. International Journal of Molecular Sciences, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC9029608/ (Accessed 2026-07-15).
3. U.S. Food and Drug Administration / Novo Nordisk (2025). WEGOVY (semaglutide) injection, for subcutaneous use - Prescribing Information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5e548d0-cc79-4c34-a3f5-e20a5b8b6564 (Accessed 2026-07-15).
4. Machado MF, Shunk T, Hansen G, Harvey C, Fulford B, Hauf S, Schuh O, Kaldas M, Arcaroli E, Ortiz J, De Gaetano J (2024). Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review. Cureus, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC11389649/ (Accessed 2026-07-15).